幽门螺杆菌根除失败的原因及补救治疗研究进展
Causes of Helicobacter pylori Eradication Failure and Research Progress on Salvage Treatment
DOI: 10.12677/md.2026.164047, PDF,   
作者: 夏 抽, 查明辛, 孙志宏, 杨 露, 万 佳, 杨 健, 董明志, 张俊丽, 张园园：云南省保山市第二人民医院消化内科，云南 保山；杨传鹏：云南省保山市第二人民医院骨科，云南 保山；夏应蝶：云南省保山市第二人民医院肾内科，云南 保山；杨荣升：云南省保山市第二人民医院耳鼻咽喉头颈外科，云南 保山
关键词: 幽门螺杆菌；根除失败；抗生素耐药；补救治疗；铋剂四联；Helicobacter pylori； Eradication Failure； Antibiotic Resistance； Salvage Treatment； Bismuth Quadruple Therapy
摘要: 幽门螺杆菌(Helicobacter pylori, Hp)是慢性胃炎、消化性溃疡、胃黏膜相关淋巴组织淋巴瘤及胃癌的重要致病因子，有效根除Hp可显著改善患者临床症状、抑制胃黏膜病变进展并降低胃癌发生风险。然而在临床工作中，Hp根除失败率仍较高。本文主要通过查阅近年来发表的文献分析Hp根除失败的主要原因及补救治疗策略的研究进展，旨在为临床制定更加规范、高效的Hp补救治疗策略提供参考依据。
Abstract: Helicobacter pylori (Hp) is an important causative factor for chronic gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Effective eradication of Hp can significantly improve patients’ clinical symptoms, inhibit the progression of gastric mucosal lesions, and reduce the risk of gastric cancer. However, in clinical work, the failure rate of Hp eradication is still high. This article mainly analyzes the main causes of Hp eradication failure and the research progress of salvage treatment strategies by reviewing the literature published in recent years, aiming to provide a reference for clinical development of more standardized and efficient Hp salvage treatment strategies.
文章引用：夏抽, 杨传鹏, 夏应蝶, 杨荣升, 查明辛, 孙志宏, 杨露, 万佳, 杨健, 董明志, 张俊丽, 张园园. 幽门螺杆菌根除失败的原因及补救治疗研究进展[J]. 医学诊断, 2026, 16(4): 359-364. https://doi.org/10.12677/md.2026.164047

参考文献

[1] O’Connor, A., O’Morain, C.A. and Ford, A.C. (2017) Population Screening and Treatment of Helicobacter pylori Infection. Nature Reviews Gastroenterology & Hepatology, 14, 230-240.
https://doi.org/10.1038/nrgastro.2016.195
[2] FitzGerald, R. and Smith, S.M. (2021) An Overview of Helicobacter pylori Infection. In: Smith, S.M., Ed., Methods in Molecular Biology, Springer, 1-14.
https://doi.org/10.1007/978-1-0716-1302-3_1
[3] 张元林. 益生菌作为辅助疗法根除幽门螺杆菌的Meta分析[D]: [硕士学位论文]. 太原: 山西医科大学, 2021.
[4] 刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 中华内科杂志, 2017, 37(6): 509-524.
[5] 武冰洁, 李晓丽. 幽门螺杆菌初次治疗失败原因分析[J]. 中国当代医药, 2018, 25(18): 34-37.
[6] 樊冰, 聂勇波, 裴晓改, 等. 幽门螺杆菌耐药性的现状、机制及应对策略[J]. 新发传染病电子杂志, 2025, 10(3): 72-77.
[7] Sugimoto, M. and Yamaoka, Y. (2009) Virulence Factor Genotypes of Helicobacter pylori Affect Cure Rates of Eradication Therapy. Archivum Immunologiae et Therapiae Experimentalis, 57, 45-56.
https://doi.org/10.1007/s00005-009-0007-z
[8] 佘菲菲, 苏东辉, 陈月秀, 等. 球形幽门螺杆菌分子生物学研究[J]. 中国微生态学杂志, 1999, 11(1): 3-6.
[9] 杨婷婷, 李雪, 刘君, 等. 幽门螺杆菌耐药机制的研究进展[J]. 山东医药, 2025, 65(12): 153-158.
[10] 张毓芹, 黄秋月, 贾晓芬, 等. 幽门螺杆菌非特异性耐药与中药抗耐药机制的研究进展[J]. 中华中医药学刊, 2025, 43(11): 131-135, 294.
[11] Kadkhodaei, S., Siavoshi, F. and Akbari Noghabi, K. (2020) Mucoid and Coccoid Helicobacter pylori with Fast Growth and Antibiotic Resistance. Helicobacter, 25, e12678.
https://doi.org/10.1111/hel.12678
[12] 成虹. 幽门螺杆菌根除治疗失败的原因[J]. 胃肠病学, 2015, (7): 385-388.
[13] van Zanten, S.J.O.V., Kolesnikow, T., Leung, V., O’Rourke, J.L. and Lee, A. (2003) Gastric Transitional Zones, Areas Where Helicobacter Treatment Fails: Results of a Treatment Trial Using the Sydney Strain Mouse Model. Antimicrobial Agents and Chemotherapy, 47, 2249-2255.
https://doi.org/10.1128/aac.47.7.2249-2255.2003
[14] 于泉, 蔡照华, 刘洁. 质子泵抑制剂在幽门螺杆菌感染根除疗法中的作用研究[J]. 实用药物与临床, 2020, 23(11): 981-984.
[15] 王娟. 不同抑酸剂四联方案及改良伴同方案根除幽门螺杆菌效果研究[D]: [硕士学位论文]. 济南: 山东大学, 2022.
[16] Kwon, Y., Kim, S., Lee, J.G. and Lee, S.P. (2023) Effects of Prior Antibiotic Use on Clarithromycin Resistance in Helicobacter pylori. Helicobacter, 28, e12974.
https://doi.org/10.1111/hel.12974
[17] 唐志锋, 高国明, 李硕权, 等. 成人幽门螺杆菌感染根除治疗失败危险因素的Meta分析[J]. 中国药房, 2025, 36(12): 1525-1529.
[18] 苏卫仙, 代金玉, 史增辉. 幽门螺杆菌根除率非药物影响因素Logistic回归分析及对策[J]. 河北医科大学学报, 2019, 40(7): 777-780.
[19] Sargýn, M. (2003) Type 2 Diabetes Mellitus Affects Eradication Rate of Helicobacter pylori. World Journal of Gastroenterology, 9, Article 1126.
https://doi.org/10.3748/wjg.v9.i5.1126
[20] Borody, T., Ren, Z., Pang, G. and Clancy, R. (2002) Impaired Host Immunity Contributes to Helicobacter pylori Eradication Failure. American Journal of Gastroenterology, 97, 3032-3037.
https://doi.org/10.1111/j.1572-0241.2002.07121.x
[21] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组, 刘文忠, 谢勇, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.
[22] Malfertheiner, P., Megraud, F., O’Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., et al. (2017) Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30.
https://doi.org/10.1136/gutjnl-2016-312288
[23] 胡伏莲. 幽门螺杆菌根除失败的原因分析和处理策略[J]. 现代消化及介入诊疗, 2010, 15(2): 108-112.
[24] Dore, M.P., Lu, H. and Graham, D.Y. (2016) Role of Bismuth in Improving Helicobacter pylori Eradication with Triple Therapy. Gut, 65, 870-878.
https://doi.org/10.1136/gutjnl-2015-311019
[25] Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J.P., Liou, J., Schulz, C., et al. (2022) Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report. Gut, 71, 1724-1762.
https://doi.org/10.1136/gutjnl-2022-327745
[26] 彭若琳, 张振玉. 近期中外幽门螺杆菌根除治疗处理共识报告对比解读[J]. 胃肠病学和肝病学杂志, 2024, 33(5): 490-4.
[27] 徐一帆, 栾富娟, 陈彦君, 等. 含钾离子竞争性酸阻滞剂的幽门螺杆菌感染再次根除治疗的效果分析: 一项真实世界研究[J]. 中华消化杂志, 2025, 45(4): 229-234.
[28] 张鑫. 钾离子竞争性酸阻滞剂与质子泵抑制剂在根除幽门螺杆菌方面的临床疗效对比分析[D]: [硕士学位论文]. 大连: 大连医科大学, 2023.
[29] Jung, Y.S., Kim, E.H. and Park, C.H. (2017) Systematic Review with Meta‐Analysis: The Efficacy of Vonoprazan‐Based Triple Therapy on Helicobacter pylori Eradication. Alimentary Pharmacology & Therapeutics, 46, 106-114.
https://doi.org/10.1111/apt.14130
[30] 何晨熙, 刘改芳. 益生菌在根除幽门螺杆菌治疗中的作用[J]. 胃肠病学和肝病学杂志, 2014, 23(7): 839-842.
[31] 蒋明远, 黄华, 路明亮, 等. 益生菌在根除幽门螺杆菌治疗中的应用及研究进展[J]. 国际消化病杂志, 2019, 39(2): 124-127.